Metagenomi TherapeuticsMGX -1.08%10 EBITDA Margin % is -1,867.95% as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Metagenomi Therapeutics ranks worse than 69.42% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Metagenomi Therapeutics EBITDA Margin % Related Terms
Metagenomi Therapeutics EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGX vs HYPD, ATYR, ACTU: EBITDA Margin % Comparison
For the Biotechnology subindustry, Metagenomi Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a EBITDA Margin % of -1,867.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #656 out of 945 companies in the Biotechnology industry, placing it in the top 69.4%.
Is Metagenomi Therapeutics' EBITDA Margin % too high?
Metagenomi Therapeutics' current EBITDA Margin % is -1,867.95%. Based on the distribution chart, Metagenomi Therapeutics ranks #656 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' EBITDA Margin % compare to HYPD and ATYR?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #656 out of 945 companies for EBITDA Margin %. This places Metagenomi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current EBITDA Margin % is -1,867.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current EBITDA Margin % of -1,867.95%. The current EBITDA Margin % is -1,867.95%. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current EBITDA Margin % is -1,867.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
